Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00004262 · ClinicalTrials.gov registry record · Phase 1
Radiation Therapy and Gadolinium Texaphyrin in Treating Patients With Supratentorial Glioblastoma Multiforme
A Phase 1 study of Adult Glioblastoma and Adult Giant Cell Glioblastoma, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
- 1
- Study location
NCT00004262 is a Phase 1 study of Adult Glioblastoma and Adult Giant Cell Glioblastoma that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 12 participants, below the 43-participant average among 14 other Adult Glioblastoma trials with a reported enrollment target (72% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00004262, a Phase 1 study of Adult Glioblastoma and Adult Giant Cell Glioblastoma, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
- 1
- Study location
Study Summary
Phase I trial to study the effectiveness of radiation therapy and gadolinium texaphyrin in treating patients who have supratentorial glioblastoma multiforme. Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs such as gadolinium texaphyrin may make the tumor cells more sensitive to radiation therapy.
Conditions Studied
Interventions
- PROCEDURE conventional surgery
- RADIATION 3-dimensional conformal radiation therapy
- RADIATION stereotactic radiosurgery
- DRUG motexafin gadolinium
- PROCEDURE magnetic resonance imaging
Study Locations (1)
Ohio
- Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University Medical Center - Columbus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 1999-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00004262
The ClinicalTrials.gov registry entry for NCT00004262 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 43-participant average among 14 other Adult Glioblastoma trials with a reported enrollment target (72% lower). The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Adult Glioblastoma appearing as the primary indexed condition, and to 5 interventions - of which conventional surgery is the first listed.
NCT00004262 reports 1 study location spanning 1 distinct geographic area - top geographies include Ohio.
Frequently Asked Questions
What is clinical trial NCT00004262 about?
NCT00004262 is a clinical study titled "Radiation Therapy and Gadolinium Texaphyrin in Treating Patients With Supratentorial Glioblastoma Multiforme". Phase I trial to study the effectiveness of radiation therapy and gadolinium texaphyrin in treating patients who have supratentorial glioblastoma multiforme. Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs such as gadolinium texaphyrin may make the tumor cells more sensitive t...
What is the current status of trial NCT00004262?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 1999-11.
What conditions does trial NCT00004262 study?
This clinical trial studies the following conditions: Adult Glioblastoma, Adult Giant Cell Glioblastoma, Adult Gliosarcoma.
What interventions are being tested in trial NCT00004262?
The interventions under investigation include: conventional surgery (PROCEDURE), 3-dimensional conformal radiation therapy (RADIATION), stereotactic radiosurgery (RADIATION), motexafin gadolinium (DRUG), magnetic resonance imaging (PROCEDURE).
Who is sponsoring clinical trial NCT00004262?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00004262 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Adult Glioblastoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Vorinostat and Temozolomide in Treating Patients With Malignant Gliomas
ACTIVE NOT RECRUITING · Phase 1
-
TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid Tumors
ACTIVE NOT RECRUITING · Phase 1
-
A Study of RNA-lipid Particle (RNA-LP) Vaccines for Newly Diagnosed Pediatric High-Grade Gliomas (pHGG) and Adult Glioblastoma (GBM)
ACTIVE NOT RECRUITING · Phase 1
-
Genetically Modified Neural Stem Cells, Flucytosine, and Leucovorin for Treating Patients With Recurrent High-Grade Gliomas
COMPLETED · Phase 1
-
Erlotinib in Treating Patients With Recurrent Malignant Glioma or Recurrent or Progressive Meningioma
COMPLETED · Phase 1
-
Bafetinib in Treating Patients With Recurrent High-Grade Glioma or Brain Metastases
COMPLETED · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.